Announcement
16 Mar 2021
On 16 March 2021, Canadian government announced providing funding to Immune Biosolutions through Phase II clinical trials of a therapeutic candidate against COVID-19.
Source
Sign in to access
Number of interventions
1
1 certainly harmful
0 likely harmful
0 liberalising
List of interventions
Implementation date
16 Mar 2021
Revocation date:
No revocation date
Updated: 16 Mar 2021
State loan
In force
On 16 March 2021, Canadian biotechnology company, Immune Biosolutions announced securing CAD 13.44 million (USD 10.8 million) from the government to develop and manufacture its immunotherapy to treat ...
Sign in to see more
Related State Acts
18 May 2021
Canada: Government announces funding for a Canadian biomanufacturing company
16 Mar 2021
Canada: KABS Laboratories secure CAD 52.2 million from the Strategic Innovation Fund
16 Mar 2021
Canada: Novocol Pharma secures funding from the Canadian government
23 Mar 2020
Canada: Government allocates CAD 792 million for the development and production of medical countermeasures to COVID-19
Threads
See all
This state act is not part of any Thread yet.